| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Julia P Gregory is Director at BHVN and has filed Form 4s across 2 companies. Julia P Gregory's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $678K at current prices.
The biggest single holding is BHVN (~$401K) as Director. Net of sales, the BHVN filings show accumulation of 9,523 shares.
Julia P Gregory has 14 Form 4 filings on record from May 2021 to October 2026, across 2 companies: Director at Nurix Therapeutics (NRIX), 2021–2026; Director at Biohaven (BHVN), 2022–2026.
The 24 reported transactions were 11 option or other derivative awards, 6 option exercises, 4 other transactions and 1 open-market sale, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $100K and 1 sale worth about $529K.
The only open-market purchase was 9,523 shares of BHVN at an average $10.50 on October 25, 2022, about $100K. Twelve months later BHVN was up 92%.
The only open-market sale was 22,583 shares of NRIX at an average $23.40 on October 14, 2026, about $529K.